edelfenbein
For a company that makes spinal implants, you'd think Biomet's (BMET) board would have a backbone. Apparently not.
The good news is that shares of BMET are now trading above private equity's $44 offer price. I hope this means the market expects a higher bid. Shareholders will vote on the offer this Friday.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment